​

ResMed (RMD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RMD Stock Forecast

ResMed (RMD) stock forecast, based on 35 Wall Street analysts, predicts a 12-month average price target of $239.90, with a high of $300.00 and a low of $213.00. This represents a 9.07% increase from the last price of $219.95.

$150 $180 $210 $240 $270 $300 High: $300 Avg: $239.9 Low: $213 Last Closed Price: $219.95

RMD Stock Rating

ResMed stock's rating consensus is Hold, based on 35 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (37.14%), 17 Hold (48.57%), 5 Sell (14.29%), and 0 Strong Sell (0.00%).

Hold
Total 35 0 5 17 13 Strong Sell Sell Hold Buy Strong Buy

RMD Price Target Upside V Benchmarks

TypeNameUpside
StockResMed9.07%
SectorHealthcare Stocks 15.45%
IndustryMedical Instruments & Supplies Stocks15.33%

Price Target Trends

1M3M12M
# Anlaysts21228
Avg Price Target$248.50$245.08$268.43
Last Closing Price$219.95$219.95$219.95
Upside/Downside12.98%11.43%22.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 2616111-19
Aug, 2616101-18
Jul, 261981-19
Jun, 262971-19
May, 263771-18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 31, 2026KeyBanc$267.00$240.3311.10%21.39%
Aug 19, 2026Redburn Partners$230.00$219.984.55%4.57%
Aug 07, 2026Robert W. Baird$213.00$212.390.29%-3.16%
Aug 07, 2026KeyBanc$255.00$223.2414.23%15.94%
Jul 21, 2026David LowUBS$300.00$195.9753.08%36.39%
Jul 16, 2026RBC Capital$234.00$198.5717.84%6.39%
Jul 15, 2026Mizuho Securities$220.00$193.0113.98%0.02%
Jul 10, 2026Jefferies$225.00$204.5010.02%2.30%
Jul 08, 2026RBC Capital$276.00$219.7525.60%25.48%
Jul 08, 2026Wells Fargo$225.00$219.752.39%2.30%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 10, 2026CitigroupNeutralNeutralhold
Aug 31, 2026KeyBancOverweightOverweighthold
Jul 21, 2026UBSBuyBuyhold
Jul 16, 2026RBC CapitalOutperformSector Performdowngrade
Jul 12, 2026CitigroupBuyNeutraldowngrade
Jul 01, 2026Goldman SachsBuyBuyhold
Apr 13, 2026Evercore ISIOutperformOutperformhold
Feb 02, 2026CitigroupBuyBuyhold
Jan 30, 2026RBC CapitalOutperformOutperformhold
Jan 30, 2026KeyBancOverweightOverweighthold

Financial Forecast

EPS Forecast

$5 $6 $7 $8 $9 $10 $11 $12 $13 $14 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$5.34$6.12$6.94$9.55$10.44---
Avg Forecast$5.71$6.50$7.73$9.41$10.38$11.34$12.14$13.55
High Forecast$5.94$6.64$7.79$9.56$11.06$12.05$12.40$13.84
Low Forecast$5.53$6.30$7.63$9.16$9.64$10.70$11.77$13.13
Surprise %-6.48%-5.85%-10.22%1.49%0.58%---

Revenue Forecast

$3B $4B $5B $6B $7B $8B Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$3.58B$4.22B$4.69B$5.15B$5.65B---
Avg Forecast$3.58B$4.24B$4.68B$5.12B$5.50B$5.89B$6.31B$6.97B
High Forecast$3.69B$4.31B$4.70B$5.16B$5.59B$5.90B$6.41B$7.08B
Low Forecast$3.49B$4.14B$4.66B$5.09B$5.26B$5.88B$6.16B$6.80B
Surprise %0.04%-0.36%0.12%0.50%2.88%---

Net Income Forecast

$0 $500M $1B $2B $2B $3B Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$779.44M$897.56M$1.02B$1.40B$1.52B---
Avg Forecast$492.41M$959.76M$1.11B$1.38B$1.48B$1.62B$1.79B$2.00B
High Forecast$621.54M$980.02M$1.34B$1.41B$1.63B$1.78B$1.83B$2.04B
Low Forecast$363.28M$929.76M$890.31M$1.35B$1.42B$1.58B$1.74B$1.94B
Surprise %58.29%-6.48%-8.26%1.40%3.17%---

RMD Forecast FAQ

Is ResMed stock a buy?

ResMed stock has a consensus rating of Hold, based on 35 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 17 Hold, 5 Sell, and 0 Strong Sell, reflecting a consensus that ResMed is a neutral investment for most analysts.

What is ResMed's price target?

ResMed's price target, set by 35 Wall Street analysts, averages $239.9 over the next 12 months. The price target range spans from $213 at the low end to $300 at the high end, suggesting a potential 9.07% change from the previous closing price of $219.95.

How does ResMed stock forecast compare to its benchmarks?

ResMed's stock forecast shows a 9.07% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the medical instruments & supplies stocks industry (15.33%).

What is the breakdown of analyst ratings for ResMed over the past three months?

  • September 2026: 5.26% Strong Buy, 31.58% Buy, 57.89% Hold, 5.26% Sell, 0% Strong Sell.
  • August 2026: 5.56% Strong Buy, 33.33% Buy, 55.56% Hold, 5.56% Sell, 0% Strong Sell.
  • July 2026: 5.26% Strong Buy, 47.37% Buy, 42.11% Hold, 5.26% Sell, 0% Strong Sell.

What is ResMed’s EPS forecast?

ResMed's average annual EPS forecast for its fiscal year ending in June 2027 is $11.34, marking a 8.62% increase from the reported $10.44 in 2026. Estimates for the following years are $12.14 in 2028, and $13.55 in 2029.

What is ResMed’s revenue forecast?

ResMed's average annual revenue forecast for its fiscal year ending in June 2027 is $5.89B, reflecting a 4.19% increase from the reported $5.65B in 2026. The forecast for 2028 is $6.31B, and $6.97B for 2029.

What is ResMed’s net income forecast?

ResMed's net income forecast for the fiscal year ending in June 2027 stands at $1.62B, representing an 6.64% increase from the reported $1.52B in 2026. Projections indicate $1.79B in 2028, and $2B in 2029.